David Bredt
Chief Scientific Officer · 3 filings · Latest: Feb 17, 2026
Rapport Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
RAPP | David Bredt | Chief Scientific Officer | Feb 19, 2026 | Option Exercise | $1.80 | 6,000 | $10.8K | 393,075 | |
RAPP | David Bredt | Chief Scientific Officer | Feb 17, 2026 | Sale | $29.02 | 8,500 | $246.7K | 387,075 | |
RAPP | David Bredt | Chief Scientific Officer | Jan 15, 2026 | Sale | $26.84 | 8,500 | $228.1K | 395,575 | |
RAPP | DAVID BREDT | — | Jan 15, 2026 | Proposed Sale | $27.42 | 17,000 | $466.1K | — | |
RAPP | DAVID BREDT | — | Jan 2, 2026 | Proposed Sale | $30.05 | 6,567 | $197.3K | — | |
RAPP | DAVID BREDT | — | Oct 15, 2025 | Proposed Sale | $24.88 | 25,500 | $634.4K | — | |
RAPP | DAVID BREDT | — | Jun 16, 2025 | Proposed Sale | $11.19 | 34,000 | $380.5K | — | |
RAPP | DAVID BREDT | — | Mar 14, 2025 | Proposed Sale | $10.02 | 25,500 | $255.5K | — |